A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
for Breast Cancer
Drug: Durvalumab
64 locations incl. Daphne
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06103864·Phase 3·Recruiting